Skip to main content
. Author manuscript; available in PMC: 2023 Nov 2.
Published in final edited form as: Cancer Discov. 2023 Nov 1;13(11):2370–2393. doi: 10.1158/2159-8290.CD-23-0131

Fig. 1. Survival outcomes of trial patients with H3K27M-DMG treated with ONC201.

Fig. 1.

(A) Kaplan-Meier curve (Y-axis, % OS; X-axis, time in months) showing OS from diagnosis for non-recurrent H3K27M-DMG patients treated with ONC201 by study (ONC201-014, blue, n=24; ONC201-018, light blue, n=11; and ONC201-014/018 combined, orange, n=35).

(B) Kaplan-Meier curve (Y-axis, % PFS; X-axis, time in months) showing PFS from start of therapy for non-recurrent H3K27M-DMG patients treated with ONC201 by study (ONC201-014, ONC201-018, and ONC201-014/018 combined).

(C) Kaplan-Meier curve (Y-axis, % OS; X-axis, time in months) showing OS from recurrence for recurrent H3K27M-DMG patients treated with ONC201 (ONC201-014/018 combined, orange, n=36).

(D) Kaplan-Meier curve (Y-axis, % PFS; X-axis, time in months) showing PFS from recurrence for recurrent H3K27M-DMG patients treated with ONC201 (ONC201-014/018 combined).